Wellington Management Group LLP Sells 29,436 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)

Wellington Management Group LLP lessened its position in Janux Therapeutics, Inc. (NASDAQ:JANX) by 67.0% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 14,498 shares of the company’s stock after selling 29,436 shares during the quarter. Wellington Management Group LLP’s holdings in Janux Therapeutics were worth $659,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Bank of New York Mellon Corp increased its position in Janux Therapeutics by 136.3% during the second quarter. Bank of New York Mellon Corp now owns 115,027 shares of the company’s stock worth $4,818,000 after acquiring an additional 66,340 shares during the period. Summit Securities Group LLC bought a new position in shares of Janux Therapeutics during the 2nd quarter worth about $29,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in Janux Therapeutics during the second quarter valued at approximately $151,000. Principal Financial Group Inc. bought a new position in shares of Janux Therapeutics during the 2nd quarter worth approximately $237,000. Finally, Rhumbline Advisers boosted its stake in shares of Janux Therapeutics by 41.2% in the 2nd quarter. Rhumbline Advisers now owns 38,008 shares of the company’s stock valued at $1,592,000 after purchasing an additional 11,085 shares in the last quarter. Institutional investors and hedge funds own 75.39% of the company’s stock.

Insiders Place Their Bets

In other Janux Therapeutics news, Director Ra Capital Management, L.P. purchased 1,200,000 shares of the stock in a transaction on Friday, October 18th. The shares were purchased at an average price of $44.75 per share, with a total value of $53,700,000.00. Following the completion of the transaction, the director now directly owns 9,317,246 shares in the company, valued at $416,946,758.50. This represents a 14.78 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Andrew Hollman Meyer sold 50,000 shares of the business’s stock in a transaction that occurred on Friday, September 27th. The stock was sold at an average price of $45.96, for a total value of $2,298,000.00. Following the transaction, the insider now directly owns 67,592 shares in the company, valued at $3,106,528.32. The trade was a 42.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 192,032 shares of company stock valued at $9,512,515 in the last three months. 29.40% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on JANX shares. Stifel Nicolaus boosted their target price on Janux Therapeutics from $70.00 to $115.00 and gave the stock a “buy” rating in a report on Tuesday, December 3rd. William Blair reissued an “outperform” rating on shares of Janux Therapeutics in a report on Tuesday, December 3rd. HC Wainwright upped their price objective on Janux Therapeutics from $63.00 to $70.00 and gave the stock a “buy” rating in a report on Tuesday, December 3rd. Leerink Partners lifted their target price on Janux Therapeutics from $79.00 to $91.00 and gave the company an “outperform” rating in a research note on Tuesday, December 3rd. Finally, UBS Group began coverage on Janux Therapeutics in a report on Thursday, October 24th. They issued a “buy” rating and a $69.00 price target on the stock. One investment analyst has rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $89.90.

Janux Therapeutics Stock Up 0.1 %

Shares of JANX stock opened at $56.83 on Friday. The firm has a fifty day moving average of $53.89 and a 200-day moving average of $47.06. Janux Therapeutics, Inc. has a 12-month low of $7.79 and a 12-month high of $71.71. The company has a market capitalization of $2.98 billion, a price-to-earnings ratio of -48.57 and a beta of 3.29.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($0.18). Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. The business had revenue of $0.44 million during the quarter, compared to analyst estimates of $1.50 million. The company’s revenue was down 82.6% compared to the same quarter last year. On average, equities analysts expect that Janux Therapeutics, Inc. will post -1.35 EPS for the current year.

Janux Therapeutics Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.